Oncology Competitive Landscape
The most crowded TA in pharma.
A live oncology competitive landscape — by indication, modality, sponsor and stage — with PoS-weighted launch projections.
"Where do we genuinely compete in onc — and where is the market saturated?"
Onc is dense — 200+ Phase 3 candidates across major indications. The map that drives strategy filters by credibility, modality cluster and PoS-weighted launch year.
Onc is the most consequential and most crowded TA. Mapping it usefully requires modality clustering, sponsor credibility filtering and PoS-weighted launch projection — done live.
What we’re seeing in the data.
Solid-tumor IO is saturated
Difficulty differentiating in 2L+ NSCLC, mCRC.
ADC platforms expand whitespace
TROP2, B7-H3, Nectin-4 ADCs.
Bispecifics deepen B-cell
CD20×CD3 reshaping hematology.
How to think about it.
-
01
Map by indication
Solid tumor / hematology / specific TAs.
-
02
Cluster by modality
IO / ADC / bispecific / cell.
-
03
Filter by credibility
Sponsor + data quality.
-
04
PoS-weighted launches
Forward 36 months.
What separates a good answer from a defensible one.
Combos redistribute share.
ADC scale-up.
CDx defines cohort.
Where the signal comes from.
Common questions.
Where is real onc whitespace?
1L rare hematology, biomarker-defined niches, ADC adjacencies.
Refresh cadence?
Live during readout windows.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist